DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Annual Results/Quarter Results
"The achievement of the guidance and by far the strongest year in the history of CGM are confirming our course. They underline the company's strong resilience in an extraordinary year. This is also reflected in the strong free cash flow," emphasizes Chief Financial Officer (CFO) Michael Rauch and adds: "The visibility will continue to be limited due to the corona virus situation. However, what we already can say is that we rather expect a stronger second half-year - similarly to the past fiscal year."
Revenues of one billion Euro expected
In light of the recent financial figures and the planned investments, Dr. Dirk Wössner, CEO of CompuGroup Medical since the beginning of January, is optimistic: "We intend to and will push forward with important future issues, such as interoperability, consumerization and datafication in healthcare, also through massive investments. Major growth opportunities will also result from this in the coming years. CGM intends to position itself optimally to take advantage of the increased efforts to digitize the healthcare system. We are convinced that these investments will already pay off in the near future."
Positive performance in all segments
In the largest segment, Ambulatory Information Systems (AIS), revenues grew in the full year by 5 % to EUR 467 million. Recurring revenues in this segment grew by 8 % to EUR 330 million in the full year. The further rollout of the Telematics Infrastructure (TI) with electronic emergency data and electronic medication plans in German medical practices and the acquisition of Epsilog at the end of 2019 contributed to this.
The Pharmacy Information Systems (PCS) segment increased revenues by 13 % in 2020 in comparison to the previous year, to a new level of EUR 135 million including TI. EBITDA increased by 18 % to EUR 38 million. In the PCS segment, through the approval of the eHealth Connector, the rollout of the Telematics Infrastructure (TI) in pharmacies was set into motion and contributed to an excellent revenue growth in the second half. Recurring revenues grew by 6 % in 2020 to EUR 76 million in comparison to the previous year.
In the newest segment, Consumer and Health Management Information Systems (CHS), revenue growth was achieved of 5 % to EUR 48 million. This growth results from a positive development in the intermedix business area. For digital healthcare applications, new products have been developed in the past months, with which both doctors and patients can prescribe/use so-called "Apps on prescription" quickly and easily.
The full quarterly report is available on the company's website at www.cgm.com/ir-publications.
About CompuGroup Medical SE & Co. KGaA
04.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
CompuGroup Medical SE & Co. KGaA
Maria Trost 21
+49 (0)261 8000 7030
+49 (0)261 8000 3200
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID:
End of News
DGAP News Service